Trial reportBMJ (Clinical research ed.)1991
Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.
Trial report in BMJ (Clinical research ed.), 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 60 citations in OpenAlex.
- Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.Diabetologia · 1994Trial
- Podocyte-targeted therapies - progress and future directions.Nature reviews. Nephrology · 2024Review
- Heart Failure in Patients with Chronic Kidney Disease.Journal of clinical medicine · 2023Review
- Review
- Review
- Medications that cause weight gain and alternatives in Canada: a narrative review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Review
- ACE inhibitors and the kidney. A risk-benefit assessment.Drug safety · 1996Review
- Glomerular morphometry in reflux nephropathy: functional and radiological correlations.Pediatric nephrology (Berlin, Germany) · 1993Article
- Nephroprotective effect of ACE inhibitors.Drugs · 1993Review
- Renal protective effect of enalapril in diabetic nephropathy.BMJ (Clinical research ed.) · 1992Article
- Angiotensin converting enzyme inhibitors and diabetic nephropathy.BMJ (Clinical research ed.) · 1992Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic origin.
designProspective, double blind, randomised 16 week study after a pretreatment period of at least three weeks.
settingOutpatient nephrology and hypertension unit. PATIENTS: 27 patients with proteinuria (greater than 300 mg protein/day) of non-diabetic origin, moderately impaired renal function (creatinine clearance 30-90 ml/min), and a pretreatment diastolic blood pressure of greater than 80 mm Hg.
interventionsTreatment with enalapril (10 mg/day, adjusted between 5 and 40 mg, if necessary) or atenolol (50 mg/day, adjusted between 25 and 100 mg if necessary) titrated against a target fall in diastolic blood pressure to less than 95 mm Hg or of greater than 10 mm Hg, or both.
main outcome measuresBlood pressure, renal haemodynamics, and urinary protein excretion.
resultsNo differences were detected between the two groups before treatment. The falls in systolic and diastolic blood pressures during treatment were not significantly different between both groups. Proteinuria fell slightly with atenolol but significantly more with enalapril (mean change -0.38 (95% confidence interval -0.78 to 0.03) v -1.2 (-1.70 to -0.69) g/day respectively, p less than 0.02) as did filtration fraction (mean change -1.8 (-2.9 to -0.7) v -3.8 (-4.9 to -2.8)% respectively. Serum potassium concentration increased with enalapril (mean change 0.63 (SD 0.51) v 0.19 (0.47) mmol/l, p less than 0.05).
conclusionsEnalapril lowers proteinuria more than atenolol in patients with non-diabetic renal disease despite a similar blood pressure lowering effect of both drugs, and its antiproteinuric effect seems to be associated with the characteristic renal haemodynamic effect of angiotensin converting enzyme inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.